Stockreport

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 [Yahoo! Finance...

ALX Oncology Holdings Inc.  (ALXO) 
PDF combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers SOUTH SAN FRANCISCO, Calif., Nov. 01, [Read more]